1y return+145.3%S&P 500 +20.9%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since December 31, 2023: $202 against $157 in the S&P 500.2
Stempoint Capital LPS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| TNGXTango Therapeutics Inc | $38.2M | 6.6% | +204.4% |
| ABVXAbivax Sa | $37.8M | 6.5% | −54.8% |
| RVMDRevolution Medicines Inc | $30.0M | 5.2% | −71.6% |
| ERASErasca Inc | $28.7M | 5.0% | +226.4% |
| TYRATyra Biosciences Inc | $20.2M | 3.5% | +63.8% |
| DNTHDianthus Therapeutics Inc | $19.6M | 3.4% | +17.5% |
| ELVNEnliven Therapeutics Inc | $17.6M | 3.0% | −52.3% |
| MLYSMineralys Therapeutics Inc | $16.3M | 2.8% | −43.5% |
| Biohaven LtdCUSIP G1110E107 | $15.8M | 2.7% | −66.6% |
| SRZNSurrozen Inc | $13.8M | 2.4% | −16.5% |
| Kiniksa Pharmaceuticals IntlCUSIP G52694109 | $13.4M | 2.3% | New |
| SRRKScholar Rock Hldg Corp | $13.2M | 2.3% | −88.5% |
| Alkermes PLCCUSIP G01767105 | $13.0M | 2.2% | +54.1% |
| TRAXFirst Tracks Biotherapeutics | $12.5M | 2.2% | New |
| PRAXPraxis Precision Medicines I | $12.5M | 2.2% | −66.9% |
| Roivant Sciences LtdCUSIP G76279101 | $12.3M | 2.1% | −54.8% |
| BIOABioage Labs Inc | $11.4M | 2.0% | −31.5% |
| CGONCg Oncology Inc | $11.3M | 2.0% | −61.3% |
| ORKAOruka Therapeutics Inc | $11.1M | 1.9% | New |
| IMVTImmunovant Inc | $10.7M | 1.8% | −81.5% |
| CELCCelcuity Inc | $10.3M | 1.8% | −18.2% |
| RLMDRelmada Therapeutics Inc | $10.1M | 1.7% | +22.2% |
| CLYMClimb Bio Inc | $9.7M | 1.7% | New |
| SYRESpyre Therapeutics Inc | $9.5M | 1.6% | −68.1% |
| Zura Bio LtdCUSIP G9TY5A101 | $8.1M | 1.4% | −9.2% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| RVMDRevolution Medicines Inc | September 30, 2025 | +301.0% | $30.0M |
| Roivant Sciences LtdCUSIP G76279101 | December 31, 2023 | +215.1% | $12.3M |
| SYRESpyre Therapeutics Inc | December 31, 2025 | +171.0% | $9.5M |
| DFTXDefinium Therapeutics Inc | March 31, 2026 | +148.9% | $6.5M |
| DNTHDianthus Therapeutics Inc | September 30, 2025 | +147.7% | $19.6M |
| WHWKWhitehawk Therapeutics Inc | September 30, 2025 | +141.1% | $4.7M |
| SRZNSurrozen Inc | June 30, 2024 | +137.0% | $13.8M |
| CELCCelcuity Inc | September 30, 2025 | +111.8% | $10.3M |
| MLYSMineralys Therapeutics Inc | June 30, 2025 | +99.4% | $16.3M |
| Biohaven LtdCUSIP G1110E107 | March 31, 2026 | +75.9% | $15.8M |
Sold off last quarter
- SNDXSyndax Pharmaceuticals Inc was $56.8M
- MBXMbx Biosciences Inc was $29.8M
- DYNDyne Therapeutics Inc was $18.4M
- EWTXEdgewise Therapeutics Inc was $18.3M
- DNLIDenali Therapeutics Inc was $16.4M
- NRIXNurix Therapeutics Inc was $9.8M
- EVMNEvommune Inc was $8.8M
- FTHSensei Biotherapeutics Inc was $8.4M
- JNJJohnson & Johnson was $7.5M
- XFORX4 Pharmaceuticals Inc was $7.0M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +25.4% | +14.8% |
| March 31, 2026 | +8.6% | −4.6% |
| December 31, 2025 | +29.5% | +2.4% |
| September 30, 2025 | +39.1% | +7.8% |
| June 30, 2025 | +1.1% | +10.5% |
| March 31, 2025 | −14.7% | −4.6% |
| December 31, 2024 | −9.0% | +2.1% |
| September 30, 2024 | +6.0% | +5.4% |
| June 30, 2024 | −12.1% | +4.0% |
| March 31, 2024 | +12.7% | +10.0% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Stempoint Capital LP Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1952142&type=13F-HR&dateb=&owner=include&count=40CIK 1952142
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1952142/000142050626001687/Filed August 14, 2026 · accession 0001420506-26-001687